Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial

Bibliographic Details
Main Author:	Kirti Singh
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2022-01-01
Series:	Indian Journal of Urology
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2022;volume=38;issue=4;spage=323;epage=324;aulast=

Similar Items

Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
by: Kirti Singh
Published: (2023-01-01)

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer
by: Jingsong Zhang, et al.
Published: (2022-10-01)

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial
by: Byung Ha Chung, et al.
Published: (2023-01-01)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
by: Meagher MF, et al.
Published: (2023-11-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
by: Koji Hatano, et al.
Published: (2023-10-01)

Systemic Triple Therapy in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
by: Tomislav Omrčen
Published: (2022-01-01)

Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
by: Abhenil Mittal, et al.
Published: (2023-04-01)

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
by: Mahasha P.J. Perera, et al.
Published: (2022-01-01)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01)

Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer
by: Hiroaki Iwamoto, et al.
Published: (2022-09-01)

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience
by: T. V. Ustinova, et al.
Published: (2021-12-01)

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
by: Belén Congregado Ruiz, et al.
Published: (2023-04-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Yasuo Oguma, et al.
Published: (2022-09-01)

Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs
by: Ferretti S, et al.
Published: (2023-06-01)

Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer
by: Darren M.C. Poon, et al.
Published: (2015-06-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Tan, J, et al.
Published: (2017)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
by: Vincenza Conteduca, et al.
Published: (2021-01-01)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
by: Dhruv Bansal, et al.
Published: (2021-01-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
by: Mark C. Markowski, et al.
Published: (2024-01-01)

Effective suppression of testosterone: the best castration therapy for hormone-sensitive prostate cancer?
by: A. A. Gritskevich, et al.
Published: (2015-12-01)

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Asta Juzeniene, et al.
Published: (2021-02-01)

A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer
by: Ephraim E. Parent, et al.
Published: (2022-09-01)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
by: Wout Devlies, et al.
Published: (2020-11-01)

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer
by: Stephanie Gleicher, et al.
Published: (2021-05-01)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
by: Sree M. Lanka, et al.
Published: (2023-04-01)

Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?
by: Claudia Mosillo, et al.
Published: (2022-08-01)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
by: Kevin K. Zarrabi, et al.
Published: (2023-06-01)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
by: Matthew D. Tucker, et al.
Published: (2019-08-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
by: Nicholas D. James, et al.
Published: (2022-11-01)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
by: Joelle El-Amm, et al.
Published: (2019-02-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Microbiome Dysbiosis Is Associated with Castration Resistance and Cancer Stemness in Metastatic Prostate Cancer
by: Matthew Uzelac, et al.
Published: (2024-03-01)

Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential
by: Leah R. Tharian, et al.
Published: (2024-03-01)

Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation
by: Joel Vargas Ahumada, et al.
Published: (2022-06-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape
by: Ashaar Al-Akhras, et al.
Published: (2024-01-01)